Table 2.
Characteristics of reported anaphylaxis (Brighton level 1, 2 or 3) after COVID-19 vaccination in Japan (14 February–21 March 2021)
| Characteristics | No. of cases (%) [n = 47] |
|---|---|
| Age, years [median (range)] | 41 (22–56) |
| Female sex | 44 (94) |
| Time to onset, min [median (range)] | 10 (< 1–480) |
| Symptom onset, min | |
| ≤ 5 | 30 (64) |
| ≤ 30 | 41 (87) |
| > 30 | 6 (13) |
| Prior allergic history | |
| Allergies and allergic reaction to food, drug, pollen, animals | 34 (72) |
| Prior anaphylaxis | 1 (2) |
| Vaccine doses | |
| First | 45 |
| Second | 2 |
| Brighton level | |
| 1 | 7 (15) |
| 2 | 33 (70) |
| 3 | 7 (15) |
| Anaphylaxis reporting rate | 8.1/100,000 |
Data are expressed as n (%) unless otherwise specified
COVID-19 coronavirus disease 2019